November 22, 2019 10:15 AM ESTUpdated 10:32 AM

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for AI upstart

ENDPOINTS

→ A longtime researcher in cardiac regenerative medicine has closed a $26 million Series B to advance his development of iPSC-derived cardiomyocytes as a treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for AI upstart

ENDPOINTS

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Japan­ese biotech pitch­ing iP­SC-de­rived med for the heart gains $26M; An­dreessen Horowitz leads $4.1M seed fund­ing for AI up­start

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for AI upstart